» Articles » PMID: 15073125

The Tumor Suppressor Gene WWOX at FRA16D is Involved in Pancreatic Carcinogenesis

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2004 Apr 10
PMID 15073125
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: WWOX (WW domain containing oxidoreductase) is a tumor suppressor gene that maps to the common fragile site FRA16D. We showed previously that WWOX is frequently altered in human lung and esophageal cancers. The purpose of this study was to delineate more precisely the role of WWOX in pancreatic carcinogenesis.

Experimental Design: We analyzed 15 paired pancreatic adenocarcinoma samples and 9 pancreatic cancer cell lines for WWOX alterations. Colony assay and cell cycle analysis were also performed to evaluate the role of the WWOX as a tumor suppressor gene.

Results: Loss of heterozygosity at the WWOX locus was observed in 4 primary tumors (27%). Methylation analysis showed that site-specific promoter hypermethylation was detected in 2 cell lines (22%) and treatment with the demethylating agent 5-aza-2'-deoxycytidine demonstrated an increase in the expression of WWOX. In addition, 2 primary tumor samples (13%) showed promoter hypermethylation including the position of site-specific methylation. Transcripts missing WWOX exons were detected in 4 cell lines (44%) and in 2 tumor samples (13%). Real-time reverse transcription PCR revealed a significant reduction of WWOX expression in all of the cell lines and in 6 primary tumors (40%). Western blot analysis showed a significant reduction of the WWOX protein in all of the cell lines. Furthermore, transfection with WWOX inhibited colony formation of pancreatic cancer cell lines by triggering apoptosis.

Conclusion: These results indicate that the WWOX gene may play an important role in pancreatic tumor development.

Citing Articles

WWOX tuning of oleic acid signaling orchestrates immunosuppressive macrophage polarization and sensitizes hepatocellular carcinoma to immunotherapy.

Liu S, Yang S, Xu M, Zhou Q, Weng J, Hu Z J Immunother Cancer. 2024; 12(11).

PMID: 39500530 PMC: 11552608. DOI: 10.1136/jitc-2024-010422.


WWOX Loses the Ability to Regulate Oncogenic AP-2γ and Synergizes with Tumor Suppressor AP-2α in High-Grade Bladder Cancer.

Kolat D, Kaluzinska Z, Bednarek A, Pluciennik E Cancers (Basel). 2021; 13(12).

PMID: 34204827 PMC: 8231628. DOI: 10.3390/cancers13122957.


In vitro and in silico assessment of the effect of WWOX expression on invasiveness pathways associated with AP-2 transcription factors in bladder cancer.

Kaluzinska Z, Kolat D, Kosla K, Orzechowska M, Bednarek A, Pluciennik E BMC Urol. 2021; 21(1):36.

PMID: 33691672 PMC: 7944886. DOI: 10.1186/s12894-021-00806-7.


Downregulated Expression of WWOX in Cervical Carcinoma: A Case-Control Study.

Srivastava S, Pratap Shahi U, Divya A, Gupta S, Singh I, Roy J Int J Mol Cell Med. 2021; 9(4):273-288.

PMID: 33688485 PMC: 7936073. DOI: 10.22088/IJMCM.BUMS.9.4.273.


Characterization of WWOX expression and function in canine mast cell tumors and malignant mast cell lines.

Makii R, Cook H, Louke D, Breitbach J, Jennings R, Premanandan C BMC Vet Res. 2020; 16(1):415.

PMID: 33129329 PMC: 7603737. DOI: 10.1186/s12917-020-02638-3.